Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational new drug applications in 2015

22 November 2017 - Clinical trial eligibility criteria are necessary to define the patient population under study and improve trial safety.  ...

Read more →

Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement

22 November 2017 - Excessive or overly restrictive eligibility criteria can slow trial accrual, jeopardise the generalisability of results, and limit ...

Read more →

Mendelian randomisation

21 November 2017 - Mendelian randomisation uses genetic variants to determine whether an observational association between a risk factor and an ...

Read more →

The “utility” in composite outcome measures

14 November 2017 - Measuring what is important to patients. ...

Read more →

Nearly half of recent EU approvals based on a single pivotal study

10 November 2017 - A recent study found that 45% of marketing authorizations granted in the EU from 2012 to ...

Read more →

Cancer drug study data was falsified, says AstraZeneca

14 October 2017 - An early lab study supporting a cancer drug bought by British drugmaker AstraZeneca was falsified, the ...

Read more →

Gatekeeping strategies for avoiding false-positive results in clinical trials with many comparisons

10 October 2017 - Clinical trials characterizing the effects of an experimental therapy rarely have only a single outcome of interest. ...

Read more →

Cheaper drug trials would lower prices: FDA chief

15 September 2017 - Decreasing the time and cost it takes to develop a drug would lower drug prices, FDA ...

Read more →

Randomised, controlled trials in health insurance systems

6 September 2017 - The well-recognised limitations of traditional randomised, controlled trials, including their cost, the nature of the patients and ...

Read more →

Statistical and clinical significance

4 September 2017 - In published research, a statistically significant result is often wrongly interpreted as representing a clinically important ...

Read more →

Major new measures to help combat rare cancers

24 August 2017 - The Australian Government is supporting major new initiatives that will improve access to clinical trials, particularly for ...

Read more →

What should patients be told about non-inferiority studies?

21 August 2017 - A non-inferiority trial is a study in which a new treatment is compared with an existing, already ...

Read more →

A cancer conundrum: too many drug trials, too few patients

12 August 2017 - With the arrival of two revolutionary treatment strategies, immunotherapy and personalised medicine, cancer researchers have found ...

Read more →

Evidence for health decision making — beyond randomised, controlled trials

2 August 2017 - A core principle of good public health practice is to base all policy decisions on the highest-quality ...

Read more →

Pharmaceutical companies’ policies on access to trial data, results, and methods: audit study

26 July 2017 - Goldacre et al. set out to identify the policies of major pharmaceutical companies on transparency of trials, ...

Read more →